Browsing Tag
Matthew Henn
1 post
Seres Therapeutics begins Phase 1b trial for SER-301 in active ulcerative colitis
Seres Therapeutics, a prominent US-based biotech company, has announced the commencement of dosing in a Phase 1b clinical…